Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.33 USD
-0.08 (-1.48%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $5.43 +0.10 (1.88%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CAPR 5.33 -0.08(-1.48%)
Will CAPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAPR
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates
Other News for CAPR
Capricor Therapeutics Updates on Duchenne Treatment Progress
Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy